Cargando…

Relacorilant With Pembrolizumab: A Phase 1b, Open-Label Study of a Selective Glucocorticoid Receptor Modulator Combined With a Checkpoint Inhibitor for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production

Adrenocortical carcinoma (ACC) is an aggressive cancer with poor response to chemotherapeutic and immunotherapeutic agents. About half of ACCs produce glucocorticoids (GC), and the presence of GC excess (hypercortisolism) is correlated with decreased survival in patients with ACC. The broad immunosu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Habra, Mouhammed Amir, Hammer, Gary D, Kebebew, Electron, Worden, Francis P, Raj, Nitya, Hallanger-Johnson, Julie E, Grauer, Andreas, Moraitis, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Adrenal
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089943/ http://dx.doi.org/10.1210/jendso/bvab048.188

Ejemplares similares

MON-163 A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients with Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia
por: Auchus, Richard Joseph, et al.
Publicado: (2020)

SUN-349 Prognostic Metabolic Signature in Aggressive Adrenocortical Carcinoma
por: Tirosh, Amit, et al.
Publicado: (2019)

RF19 | PSUN33 Adrenocortical Carcinoma as a Rare Manifestation of Birt-Hogg-Dubé Syndrome
por: Else, Tobias, et al.
Publicado: (2022)

SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials
por: Kroiss, Matthias, et al.
Publicado: (2019)

PSAT010 Severe Cholestatic Jaundice (Stauffer Syndrome) as a Rare Paraneoplastic Manifestation in Adrenocortical Carcinoma
por: Murvelashvili, Natia, et al.
Publicado: (2022)

MON-193 Glucocorticoid Excess and Its Association with Metabolic and Cardiovascular Complications in Primary Aldosteronism
por: zhu, Ke ying, et al.
Publicado: (2020)

SAT-175 Trial in Progress Interim Report: A Phase II Clinical Trial Using Single Agent Cabozantinib in Advanced Adrenocortical Carcinoma
por: Bedrose, Sara Shokry Daniel, et al.
Publicado: (2020)

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant
por: Pivonello, Rosario, et al.
Publicado: (2022)

PMON165 Favorable Liver Safety Profile of the Selective Glucocorticoid Receptor Modulator Relacorilant in Healthy and Hepatically Impaired Adults and in Patients with Cushing Syndrome
por: Moraitis, Andreas, et al.
Publicado: (2022)

Glucocorticoids and Pheochromocytoma- a Recipe for Disaster?
por: Chandrashekar, Nikhitha, et al.
Publicado: (2021)

PSAT082 A Survey of Patients Living with CAH Assessing Their Perceptions on Glucocorticoid Regimen and Glucocorticoid-Associated Side Effects
por: Barnes, Chris, et al.
Publicado: (2022)

Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition
por: Viho, Eva M G, et al.
Publicado: (2022)

RF33 | PSAT92 Glucocorticoid Excess Alters Metabolic Rate in Male and Female C57BL/6J Mice
por: Tsintzas, Kostas, et al.
Publicado: (2022)

THU035 Impact Of Surgery Or Medical Treatment With The Selective Glucocorticoid Receptor Modulator Relacorilant On Hypercoagulopathy In Patients With Cushing Syndrome
por: Simeoli, Chiara, et al.
Publicado: (2023)

SUN-451 A Randomized-Withdrawal, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Selective Glucocorticoid Receptor Antagonist, Relacorilant, in Patients with Cushing Syndrome (GRACE Study)
por: Auchus, Richard, et al.
Publicado: (2019)

LBODP010 A Case of Glucocorticoid Resistance Syndrome
por: Sudhakar, Shwetha Mallesara, et al.
Publicado: (2022)

SUN-388 Immune Checkpoint Inhibitor Nivolumab in Advanced or Recurrent Adrenocortical Carcinoma
por: Akunjee, Munaza, et al.
Publicado: (2019)

PSUN13 Transcriptional and epigenetic landscapes of adrenocortical tumors
por: Lerario, Antonio, et al.
Publicado: (2022)

The Impact of Cannabinoid Exposure on Glucocorticoid Receptor Signaling in Neural Stem Cells
por: Gill, Nikki, et al.
Publicado: (2021)

Assessment of Chronic Supraphysiological Glucocorticoid Dosing Needs of Patients With Adrenal Insufficiency
por: Mun, Jeff, et al.
Publicado: (2021)

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
por: Munster, Pamela N., et al.
Publicado: (2022)

The Case of a Glucocorticoid-Induced Myopathy & Myasthenia Gravis Combination: Is There a Border?
por: Dzherieva, Irina, et al.
Publicado: (2021)

SUN-207 Modelling Long Term Glucocorticoid-Induced HPA Axis Suppression in Mice
por: Romano, Nicola, et al.
Publicado: (2020)

Confirmation of Feasibility of Selective Glucocorticoid Replacement Following Unilateral Adrenalectomy for Hypercortisolism and Primary Aldosteronism
por: DeLozier, Olivia Mallory, et al.
Publicado: (2021)

OR04-6 Comprehensive Profiling of the MELK Inhibitor OTSSP167's Action and Its Effect on Sensitization to Wee1 Inhibitor AZD1775 in a Spectrum of ACC Models
por: Bagby, Stacey, et al.
Publicado: (2022)

SAT-361 Rapid Glucocorticoid Regulation of Adrenoreceptor Trafficking Desensitizes CRH Neurons to Noradrenergic Activation
por: Weiss, Grant, et al.
Publicado: (2019)

SUN-217 Skin Glucocorticoid Metabolism in Burn Injury: Towards Novel Treatments That Reduce Scarring
por: Tsai, Kevin Hung-Yueh, et al.
Publicado: (2020)

MON-189 Evaluation of Adrenal Insufficiency and Recovery in Rheumatology Patients on Long-Term Glucocorticoid Therapy
por: Sagar, Rebecca, et al.
Publicado: (2020)

MON-168 Peri-Operative Glucocorticoids in Patients Having Total Joint Replacements: Help or Harm?
por: Chukir, Tariq, et al.
Publicado: (2020)

MON-159 High Mortality Rate in Oral Glucocorticoid Users: A Case-Control Study
por: Einarsdottir, Margret, et al.
Publicado: (2020)

Comparative Transcriptional Analysis of Patient Responders Versus Non-Responders to Glucocorticoid Treatment for Bronchopulmonary Dysplasia
por: Shi, Victoria J, et al.
Publicado: (2021)

SAT-391 Perioperative Glucocorticoid Therapy for Patients with Adrenal Insufficiency: Dosing Based on Hydrocortisone Pharmacokinetic Data
por: Rahhal, Marie-Noel, et al.
Publicado: (2019)

OR19-04 Glucocorticoid Production in the Nervous and Immune Systems: Evidence for a Local HPA Axis Homolog
por: Salehzadeh, Melody, et al.
Publicado: (2020)

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
por: Pivonello, Rosario, et al.
Publicado: (2021)

MON-179 Association Between Long-Term Prednisolone Induced Adrenal Insufficiency and Polymorphisms in the Glucocorticoid Receptor Gene
por: Borresen, Stina Willemoes, et al.
Publicado: (2020)

SAT-LB44 WNT2B Regulates Adrenocortical Progenitor Cell Fate And Zona Glomerulosa Identity In Vivo
por: Little, Donald W, et al.
Publicado: (2020)

Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
por: Pivonello, Rosario, et al.
Publicado: (2022)

Adrenocortical Carcinoma and Synchronous Malignancies
por: Guerrero, Marlon A., et al.
Publicado: (2010)

Wnt2b Is Essential for Adrenocortical Progenitor Cell Fate and Zona Glomerulosa Identity in Vivo
por: Little, Donald W, et al.
Publicado: (2021)

MON-183 Adrenal Androgen Control and Steroidal Side Effects in Adolescents and Adults with Congenital Adrenal Hyperplasia Treated with Glucocorticoids
por: Falhammar, Henrik, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7ocqo355q5ip0a5b9h43m0rokt